SAB Biotherapeutics (NASDAQ:SABS – Free Report) had its target price raised by Chardan Capital from $3.00 to $25.00 in a research note published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Separately, HC Wainwright decreased their target price on shares of SAB Biotherapeutics from $10.00 to $6.00 and set […]
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SAB Biotherapeutics to Present at the Needham Virtual globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright Trims SAB Biotherapeutics (NASDAQ:SABS) Target Price to $6.00 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
SAB Biotherapeutics, Inc.: SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.